technology platform capable of identifying novel treatments for diseases with unmet medical needs. Symthera is the first biotechnology company to apply the power of network theory to drug discovery and has pioneered a novel approach to modulating the immune network. Symthera has identified peptides motifs using systems biology approaches of sequence sharing patterns within and between cancer-associated proteins which contribute to the regulation of cell cycle progression.